Streetbeat News

Products Services

BHVN

Biohaven shares rose after the company announced that its study of Troriluzole for treating spinocerebellar ataxia met the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:43 am

ATHE

Alterity Therapeutics will present key Phase 2 data at the International Congress of Parkinson's Disease and Movement Disorders in 2024. The presentations will include interim data from their ATH434-202 trial for multiple system atrophy.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:40 am

BWMN

Bowman Consulting Group Ltd. (NASDAQ:BWMN) has secured a significant contract with the Illinois Department of Transportation to manage and design a 15.6-mile corridor of I-55. This project is part of Illinois' $45 billion Rebuild Illinois infrastructure program, aiming to improve safety and reduce congestion.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:38 am

ALRN

Aileron Therapeutics has completed enrollment for the Phase 1b trial of its IPF drug, LTI-03. The trial aims to assess the safety and tolerability of the drug, with topline data expected soon. Positive trends were previously observed in the low-dose cohort.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:37 am

ELEV

Elevation Oncology's EO-3021 has received FDA Fast Track designation for treating advanced gastric cancer, highlighting its potential to address unmet medical needs. The designation is based on promising early clinical trial results.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:36 am

BCAB

CNTX

Context Therapeutics has secured global rights to develop and commercialize BioAtla's cancer therapy BA3362, a Nectin-4 x CD3 TCE. This agreement allows Context to advance its pipeline of TCE assets, while BioAtla focuses on its lead clinical CAB programs. BioAtla will receive up to $133.5 million in payments.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:34 am

RKLB

ROKT

UFO

Rocket Lab USA, Inc. successfully launched its 53rd Electron mission, deploying five satellites for Kinéis, boosting its stock price. The mission supports global IoT connectivity, with Rocket Lab's stock gaining 71% over the past year. Investors can access RKLB through ETFs like Procure Space ETF and SPDR S&P Kensho Final Frontiers ETF.

Portfolio Pulse from Lekha Gupta

September 23, 2024 | 11:33 am

BHVN

Biohaven Ltd. (NYSE:BHVN) announced positive 3-year results for troriluzole in treating Spinocerebellar Ataxia (SCA), showing significant slowing of disease progression. The study met its primary endpoint, and Biohaven plans to submit a New Drug Application to the FDA in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:32 am

ARWR

Arrowhead Pharmaceuticals has filed for regulatory clearance to start a Phase 1/2a trial for ARO-INHBE, an RNAi therapeutic for obesity. The trial will assess the safety and efficacy of ARO-INHBE alone and in combination with tirzepatide. Arrowhead plans to file for another trial for ARO-ALK7 by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:31 am

GE

MSFT

GE Aerospace has partnered with Microsoft to implement the AI Wingmate platform, powered by Azure AI, to enhance productivity and innovation among its 52,000 employees. This collaboration aims to improve safety, sustainability, and supply chain efficiency in the aerospace industry.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:21 am